Opinion|Videos|September 6, 2024
Future Directions for Type 2 Inflammation Management
Author(s)Reynold A. Panettieri Jr, MD
Reynold A. Panettieri Jr., MD, examines the application of biologic therapies in the treatment of respiratory conditions.
Advertisement
Episodes in this series
- Biologics are currently available for asthma management and being studied in COPD patients. Where do you envision the potential place of biologic therapies in the treatment algorithm for patients with type 2 inflammation-driven COPD?
- How does the route of administration impact the treatment selection?
- What emerging therapies for type 2 inflammation related to respiratory diseases are you most excited about? What are clinical trial data showing in terms of exacerbation and hospitalization rates, patient quality of life, and general disease management?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule
2
New Dermatologic Therapies Make Waves at Maui Derm 2026
3
Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations
4
Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust
5
